Dose escalation study of no-carrier-added 131I- metaiodobenzylguanidine for relapsed or refractory neuroblastoma: New approaches to neuroblastoma therapy consortium trial

Journal of Nuclear Medicine

Volumn 53, Issue 7, 2012, Pages 1155-1163

  Matthay, Katherine K ^a   Weiss, Brian ^b   Villablanca, Judith G ^c   Maris, John M ^d   Yanik, Gregory A ^e   DuBois, Steven G ^a   Stubbs, James ^f   Groshen, Susan ^g   Tsao Wei, Denice ^g   Hawkins, Randall ^a   Jackson, Hollie ^h   Goodarzian, Fariba ^h   Daldrup Link, Heike ⁱ   Panigrahy, Ashok ^j   Towbin, Alexander ^k   Shimada, Hiroyuki ^h   Barrett, John ^l   LaFrance, Norman ^l   Babich, John ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f Radiation Dosimetry Systems Inc   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h CHLA   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

^j CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^k CCHMC   (United States)

^l A Subsidiary of Lantheus Holdings   (United States)

more..

Author keywords

131I MIBG; Dosimetry; Neuroblastoma; No carrier added

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131;

ADULT; APPLICATION SITE REACTION; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG UPTAKE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LIVER DISEASE; MALE; METABOLIC DISORDER; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUROLOGIC DISEASE; NEUTROPENIA; PAIN; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION ABSORPTION; RADIATION DOSE; TREATMENT RESPONSE; WHOLE BODY RADIATION;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADULT; BRAIN NEOPLASMS; CHEMISTRY, PHARMACEUTICAL; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; QUALITY OF LIFE; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS; SOFTWARE; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84863460418     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.098624     Document Type: Article

References (24)

1. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-1173. (Pubitemid 29480654)
2. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324-1334.
3. 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction. Br J Cancer. 1994;70:97-101.
4. Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008;52:403-418.
5. DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol. 2008;35(suppl 1):S35-S48.
6. 131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br J Cancer. 1999;81:1378-1384.
7. 131I]metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma. J Nucl Biol Med. 1991;35:202-206.
8. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131- metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25:1054-1060. (Pubitemid 46596756)
9. 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol. 1998;16:229-236.
10. Matthay KK, Quach A, Huberty J, et al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol. 2009;27:1020-1025.
11. 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharm. 2010;25:299-308.
12. Mairs RJ, Cunningham SH, Russell J, et al. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation. J Nucl Med. 1995;36:1088-1095.
13. Coleman RE, Stubbs JB, Barrett JA, de la Guardia M, Lafrance N, Babich JW. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid. Cancer Biother Radiopharm. 2009;24:469-475.
14. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477. (Pubitemid 23228250)
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
16. Messina JA, Cheng SC, Franc BL, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer. 2006;47:865-874. (Pubitemid 44656106)
17. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027. (Pubitemid 43733519)
18. Quach A, Ji L, Mishra V, et al. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer. 2011;56:191-201.
19. 131I- metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol. 2003;25:543-547.
20. Matthay KK, Panina C, Huberty J, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with 131I-MIBG. J Nucl Med. 2001;42:1713-1721. (Pubitemid 33131334)
21. 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med. 2009;50:1518-1524.
22. 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother Radiopharm. 2007;22:105-112.
23. 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys. 2010;37:4861-4867.
24. Wolden SL, Gollamudi SV, Kushner BH, et al. Local control with multimodality therapy for Stage 4 neuroblastoma. Int J Radiat Oncol Biol Phys. 2000;46:969-974. (Pubitemid 30114410)